
AdAlta (ASX:1AD) aims to become a leader in cell therapy for cancer, providing a pathway for innovative cellular immunotherapies for solid cancers originating in Asia, and China particularly, to reach western regulated markets. Subsidiary company, AdCella, in-licenses first in class or best in class assets, establishes manufacturing and generates clinical data in Australia under a US IND at substantially lower cost than in the US. We act as a force multiplier for our Asian partners, enabling them to reach western markets at no cost but while sharing the upside with us. AdAlta also has a…
Annual Revenue$1M to $5M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.